Show simple item record

dc.contributor.authorDyall, J.
dc.contributor.authorGross, R.
dc.contributor.authorFrieman, M.B.
dc.date.accessioned2020-03-27T15:13:14Z
dc.date.available2020-03-27T15:13:14Z
dc.date.issued2017
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85034083736&doi=10.1007%2fs40265-017-0830-1&partnerID=40&md5=32b04da678f019a22f9c7f5dc98e5722
dc.identifier.urihttp://hdl.handle.net/10713/12398
dc.description.abstractNo specific antivirals are currently available for two emerging infectious diseases, Middle East respiratory syndrome (MERS) and severe acute respiratory syndrome (SARS). A literature search was performed covering pathogenesis, clinical features and therapeutics, clinically developed drugs for repurposing and novel drug targets. This review presents current knowledge on the epidemiology, pathogenesis and clinical features of the SARS and MERS coronaviruses. The rationale for and outcomes with treatments used for SARS and MERS is discussed. The main focus of the review is on drug development and the potential that drugs approved for other indications provide for repurposing. The drugs we discuss belong to a wide range of different drug classes, such as cancer therapeutics, antipsychotics, and antimalarials. In addition to their activity against MERS and SARS coronaviruses, many of these approved drugs have broad-spectrum potential and have already been in clinical use for treating other viral infections. A wealth of knowledge is available for these drugs. However, the information in this review is not meant to guide clinical decisions, and any therapeutic described here should only be used in context of a clinical trial. Potential targets for novel antivirals and antibodies are discussed as well as lessons learned from treatment development for other RNA viruses. The article concludes with a discussion of the gaps in our knowledge and areas for future research on emerging coronaviruses.en_US
dc.description.sponsorshipFunding This work was supported in part by the Division of Intramural Research and Division of Clinical Research, National Institute of Allergy and Infectious Diseases. This work was funded in part through Battelle Memorial Institute's prime contract with the US National Institute of Allergy and Infectious Diseases (NIAID) under Contract No. HHSN272200700016I.en_US
dc.description.urihttps://doi.org/10.1007/s40265-017-0830-1en_US
dc.language.isoen_USen_US
dc.publisherSpringer International Publishingen_US
dc.relation.ispartofDrugs
dc.subject.meshMiddle East Respiratory Syndrome Coronavirusen_US
dc.subject.meshSevere Acute Respiratory Syndromeen_US
dc.subject.meshDrug Therapyen_US
dc.subject.meshSARS Virusen_US
dc.subject.meshCoronavirus Infectionsen_US
dc.titleMiddle East Respiratory Syndrome and Severe Acute Respiratory Syndrome: Current Therapeutic Options and Potential Targets for Novel Therapiesen_US
dc.typeArticleen_US
dc.identifier.doi10.1007/s40265-017-0830-1
dc.identifier.pmid29143192
dc.identifier.ispublishedNo


This item appears in the following Collection(s)

Show simple item record